Repotrectinib

Publication Details

Estimated reading time: 1 minute

CASRN: 1802220-02-5

image 394857851 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of repotrectinib during breastfeeding. Because repotrectinib is 94.5% bound to plasma proteins, the amount in milk is likely to be low and oral bioavailability is less than 50%; however, the drug’s half-life is about 50 hours in adults. The manufacturer recommends that breastfeeding be discontinued during repotrectinib therapy and for 10 days after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Repotrectinib

CAS Registry Number

Drug Class

Breast Feeding

Lactation

Milk, Human

Antineoplastic Agents

Enzyme Inhibitors

Protein Kinase Inhibitors

Signal Transduction Inhibitors

Tyrosine Kinase Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.